By Health and Medicine
genetic analyses of the virus have not found any substantial changes which would effectively disguise it from the immune system.
From 'COVID Toes' to Hives, These Are the Skin Conditions Dermatologists Think Could Be Signs of CoronavirusBy Isabella
Dermatologists around the world are gathering data on what may be largely overlooked symptoms of COVID-19: skin conditions ranging from rashes to “pseudo-frostbite.”
Many viral illnesses—including chickenpox, measles and mononucleosis—are accompanied by telltale skin rashes, often a result of the body’s heightened inflammatory response while fighting off infection. Though more research is needed, a growing number of case reports and preliminary studies suggest SARS-CoV-2, the virus that causes COVID-19, can also affect the skin.
In late March, an Italian physician submitted a letter to the editor of the Journal of the European Academy of Dermatology and Venereology, describing skin conditions that affected about 20% of 88 COVID-19 patients analyzed in the Lombardy region of Italy. Most of them developed a red rash on their torsos, while a few suffered hives or blisters resembling chickenpox. Then, in early April, a dermatology organization representing more than 400 French dermatologists issued a statement noting that among probable COVID-19 patients they had seen skin symptoms including hives, red rashes and frostbite-like lesions on the extremities. And finally, in mid-April, in a letter to the editor of the Journal of the American Academy of Dermatology, a group of Italian physicians described a chickenpox-like rash as “a rare but specific COVID-19-associated skin manifestation.”
Hello guest! Please register or sign in (it's free) to view the hidden content.
Hello guest! Please register or sign in (it's free) to view the hidden content. “This has been on people’s radar for quite a while,” he said. “Somebody on a different floor sneezes …The particle can stay airborne long enough to go all the way through the system and then pop out in somebody else’s office.”
By Health and Medicine
New Coronavirus (COVID-19) Drugs: Remdesivir, Tocilizumab (Actemra), and Leronlimab | New Coronavirus Treatment Remdesivir, Tocilizumab, and Leronlimab are new medications against Coronavirus (COVID-19) that are being explored. Besides hydroxychloroquine, these are other medications being investigated in the context of a clinical trial and some for compassionate use to treat coronavirus (COVID-19). Remdesivir, developed by Gilead Sciences Inc., is an investigational broad-spectrum antiviral treatment that was previously tested in humans with Ebola and had shown promise in animal models for treating Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses. Currently Gilead Sciences has made Remdesivir available for coronavirus clinical trials and to more than 1800 people on a compassionate use basis. The hope is that the results from the phase 3 clinical trials will be available by the end of May, 2020. Tocilizumab is a monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). And by inhibiting the entire receptor complex, you block the signal to induce more inflammation from coronavirus.
In a recent study from China, researchers noted Tocilizumab appears to be an effective treatment option in COVID‐19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL‐6, the repeated dose of the Tocilizumab is recommended. Leronlimab, made by the Canadian pharmaceutical Cytodyn, is a CCR5 reecptor inhibitor drug that was developed to treat HIV. The CCR5 receptor stands for “chemokine receptor type 5” and is expressed on t-cells, macrophages and even on breast and prostate cancer cells. By blocking this receptor, the principle is that you are block cytokines that direct cell movement for coronavirus (COVID-19). And by blocking the movement, you don’t bring immune cells to the site of infection from coronavirus (COVID-19), thus decreasing the risk of a cytokine storm. While there are many more drugs still in the pipeline to treatment COVID-19, these are the new drugs I feel have the most promise and are moving along to phase 3 clinical trials and onto the consumer market.
- Dr. Yo.
NYC Doc Says Ventilator Protocol Must Be Changed ASAP: Give O2, NOT Pressure. Pressure is Permanently Damaging Patient Lungs & Killing Them. Italy Study Confirms.By Michael Krewson
Patients need OXYGEN NOT PRESSURE!!! The ventilators are likely causing lung damage because of PRESSURE. 100,000 - 250,000 Americans at risk of lung injury. Change can happen. The time is NOW!! #oxygennotpressure #thetimeisnow
By Michael Krewson
The researchers emphasize that this is not a project for typical do-it-yourselfers to undertake, since it requires specialized understanding of the clinical-technical interface, and the ability to work in consideration of strict U.S. Food and Drug Administration specifications and guidelines.
This is for medical device manufacturers (and maybe other industries with skill in sterile equipment manufacturing, if need dictates) to have a design that can be fabricated more quickly and cheaply than existing designs to get around the current bottlenecks in the supply chain.
- Sure, but having a non-sterile non fda approved respirator is probably better than having no respirator.
By Michael Krewson
A 30-year-old nurse from Belgium died in hospital on Thursday after becoming infected with the coronavirus. The disease spread to her heart and it was fatal. ,, She was sporty, did crossfit. We can't understand it, "say her parents. Isaura Castermans is said to be the youngest victim in Belgium to succumb to the virus.
For-Profit healthcare. You won't buy in excess, just enough, if not a little less.
And now, massive fortunes are being made from the sale of ppe...
Mainland China: 1,380 deaths among 63,851 cases, mostly in the central province of Hubei.
— Hong Kong: 56 cases, 1 death
— Macao: 10
— Japan: 259, including 218 from a cruise ship docked in Yokohama, 1 death
— Singapore: 67
— Thailand: 33
— South Korea: 28
— Malaysia: 19
— Taiwan: 18
— Vietnam: 16
— Germany: 16
— United States: 15. Separately, one U.S. citizen died in China
— Australia: 14
— France: 11
— United Kingdom: 9
— United Arab Emirates: 8
— Canada: 7
— Philippines: 3 cases, including 1 death
— India: 3
— Italy: 3
— Russia: 2
— Spain: 2
— Belgium: 1
— Nepal: 1
— Sri Lanka: 1
— Sweden: 1
— Cambodia: 1
— Finland: 1